Reports and Insights (R&I) has published a new report titled, “Vulvodynia Treatment Market: Opportunity Analysis and Future Assessment 2020 to 2028”
Global Vulvodynia Treatment Market, by Drug Class (Anticonvulsant, Tricyclic Antidepressant, Serotonin-norepinephrine reuptake inhibitors, Hormone, Nerve Block, Local Anesthetic, and Others), by Mode Of Administration (Oral, Topical, and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.
The global vulvodynia treatment market in 2020 is estimated for more than US$ 4.9 Bn and expected to reach a value of US$ 7.7 Bn by 2028 with a significant CAGR of 5.9%.
As per the report, the global vulvodynia treatment market is majorly driven by the factors like tampon insertion, prolonged sitting, cycling or horseback riding, sexual intercourse, extreme gynecologic examination, and wearing tight undergarments.
Moreover, the growing issues and the increasing initiatives to create awareness about women healthcare coupled with the adoption of advanced technology in improving healthcare facilities are also expected to favor steady market growth during the forecast year. The involvement of diagnostic services for the betterment of existing treatment also boosts the growth of the market.
Other factors including the accessibility of numerous generic and authentic products, mounting the occurrence of vulvodynia, and the on-going research and development activities enhancing the effectiveness of the treatment also boost the market growth. For instance, an NIH-funded Harvard study revealed the count of approximately 6 million women in America is expected to suffer from Vulvodynia.
On the contrary, extremely low awareness about the disease, its causes, and the treatment options in emerging nations coupled with the penetrating side effects resulting from the treatment medications likely to restrict the market growth. On the other hand, the extended availability of off-label drugs offers a lucrative growth opportunity during the upcoming years.
Furthermore, Reports and Insights (R&I) Study identifies that the availability of numerous generic products upsurges the chances of the treatment medication thereby boosting the market growth. Besides, the study published by Schlaeger, assistant professor at the University of Illinois at Chicago's College of Nursing revealed that approximately $2 million grant was received from the National Institute of Health's National Institute of Child Health and Human Development to optimize the study, elaborating the effect of acupuncture on the treatment of vulvodynia published on October 2017.
R&I Study identifies some of the key participating players in the Vulvodynia Treatment market globally are Allergan plc., AstraZeneca Plc., Depomed Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., National Vulvodynia Association, Noven Pharmaceuticals, Inc., Pfizer Inc., Sanofi Aventis, and Upsher-Smith Laboratories, LLC.
Reports and Insights (R&I) is committed to provide deep insights that serve as a creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client's needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
Reports and Insights (R&I)
For Sales Queries: firstname.lastname@example.org
For New Topics and Other Info: email@example.com